Not sure why everyone forgets about China and are so obsessed about BUB's USA activities.
USA quarterly revenue is at $17M and grew 26% over pcp.
China quarterly revenue is $7M and growing at 70% over pcp.
Extrapolate this out over the next few quarters.
Let's say for argument's sake both maintain similar revenue growth over the course of this calendar year.
USA would generate $21.5M in Q3 and $27M in Q4 and $34M in 1Q26.
China would generate $12M in Q3, $20M in Q4 and $34M in 1Q26.
In other words, by the start of the next FY China sales will likely already be overtaking USA. China will also be more profitable and easier for BUB to compete compared to USA where the US government enforces and subsidizes a monopoly of the big 4 U.S. formula producers. There is a reason that some companies elected not to pursue permanent FDA approval after being granted the temporary exemption. There are a number of factors that put a cap on the amount of earnings growth that can be achieved in the long run in USA.
BUB Price at posting:
11.3¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)